Effect of Upadacitinib on Atopic Hand Eczema in Patients With Moderate-to-Severe Atopic Dermatitis: Results From Two Randomised Phase 3 Trials.

Eric L SimpsonK RahawiX HuA D ChuC NduakaS JazayeriPeter A LioC LyndeM L A Schuttelaar

Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2023)

Upadacitinib 15 mg and 30 mg monotherapy provided rapid and sustained improvement in atopic hand eczema compared to placebo through week 16 in patients with moderate-to-severe AD. At week 16, the observed mean improvements in HECSI score in upadacitinib-treated patients were clinically meaningful based on previous interpretability studies. These results suggest that upadacitinib may be an effective treatment option for atopic hand eczema in patients with moderate-to-severe AD.

Keyphrases

atopic dermatitis
high intensity
end stage renal disease
early onset
placebo controlled
newly diagnosed
clinical trial
open label
chronic kidney disease
ejection fraction
combination therapy
prognostic factors
drug induced
study protocol
peritoneal dialysis